Regeneron Pharmaceuticals, Inc. (REGN) — Fair Value Analysis
Base-case fair value (P50): $860.59 · Current price: $803.48 · Verdict: Fairly Valued
The Verdict on REGN
Our Monte Carlo simulations indicate Regeneron Pharmaceuticals Inc (REGN) is currently Fairly Valued. Trading at $803.48, REGN's median fair value (P50) is calculated at $860.59, representing an implied +7.1% upside. This narrow band suggests that, based on thousands of forward scenarios, the market's current appraisal of REGN closely aligns with its intrinsic valuation, leaving little immediate discount or premium for investors. Despite this, the consistent valuation across various simulated pathways underscores the robustness of this fair value assessment.
How REGN stacks up against peers
REGN's operational and financial health registers as average when compared to its sector peers. This average quality tier is factored into our Monte Carlo simulations, shaping the range and probabilities of its potential future fair values. While an average quality tier implies no significant competitive edge or disadvantage in fundamental metrics, it reinforces the Monte Carlo finding that REGN's current price of $803.48 is in equilibrium with its median fair value of $860.59. Companies with higher quality tiers might exhibit more significant potential upside in bull-case scenarios, while those with lower tiers could face steeper downside risks.
What this means for investors
For investors, REGN's Fairly Valued verdict, supported by a modest +7.1% difference between $803.48 and $860.59, implies that substantial immediate alpha may be limited. While our Monte Carlo analysis offers a comprehensive view across numerous forward-looking scenarios, the current data suggests REGN is trading near its inherent worth. Investors seeking deeper insights into REGN’s potential will want to understand the full probability distribution, including the precise downside scenario and bull case. Sign up for a free FairCurve account to access the full Monte Carlo distribution, including bear (P10) and bull (P90) targets, and track REGN's fair value as new fundamentals are released.
Frequently Asked Questions
Is REGN overvalued or undervalued right now?
Based on our Monte Carlo simulations, REGN is currently deemed Fairly Valued, with its current price of $803.48 closely aligning with its median fair value of $860.59.
What is the bear case and bull case for REGN?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, along with the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios here.
How does FairCurve calculate REGN's fair value?
FairCurve employs Monte Carlo simulation, running thousands of forward-looking scenarios based on a dynamic valuation model, to generate a probabilistic fair value distribution for REGN.
How can I track REGN's fair value as it changes?
You can add REGN to your free FairCurve watchlist to receive daily fair-value updates and instant re-valuation whenever new earnings or fundamental data are released.